预约演示
Joe Jimenez's Aditum finds fresh twist on old idea, paying $10M for autoimmune BTK inhibitorautoimmune BTK inhibitor
2023-04-28
临床1期临床申请
Joe Jimenez, co-founder and managing director of Aditum Bio
Joe Jimenez’s VC fund has ponied up $10 million tAditum Biorack a nut that defeated a who’s who of top drug developers. The outlay gives the fund, Aditum Bio, near-global rights to a BTK inhibitor with a twist, which is in development in autoimmune diseases including rheumatoid arthritis.
A push to treat rheumatoid arthritis by targeting the kinase sputtered in the wake of the failure of assets such as Eli Lilly’s poseltinib and faltAditum Bioer when AbbVie’s bid to coBTKne inhibition of BTK and JAK also came up short. Expautoimmune diseasesoffers a rorheumatoid arthritismatoid arthritis drug have fallen to such an extent that The Lancet Rheumatology recently ran a comment piece titled “Et tu, Brutinib? Demise of a kinase target in rheumatoid arthritis?”
Against that bacrheumatoid arthritiset up by Jimenez and Mark Fishman, respectively the former CEO of Novartis and president of poseltinibis Institutes for BioMedicaAbbViearch, has bet $10 million upfronBTKn a pJAKlinical BTK program and created a bioteBTKto take it into the clinic.rheumatoid arthritisrheumatoid arthritis
The deal, which is worth up to $477 million once milestones are factored in, gives the Aditum VC fund Novartisbal rights to DWP21338Novartisoped by Korea’s Daewoong Pharmaceutical, the molecule is a dual inhibitor of BTK aBTKITK. The targets are implicated in the activation of B cells and T cells, suggesting the molecule may have synergistic therapeutic efficacy that improves on the lackluster performance of BTK inhibitors in some indications to date. Aditum Bio has bought into the idea.
Aditum Bio has created Vitalli Bio, its ninth portfolio company, to take the drug candiAditumnto the clinic. Human tests of DWP213388molecule, now renamed VDaewoong Pharmaceutical start later this year. Daewoong receiBTK FDA ITKarance to study the drug in humans last year.BTK inhibitorsBTKAditum Bio
Aditum Bioas a unique pVitalli Bio selectively inhibits a range of relevant immune cells, suggesting it has the potential to represent a safe and effectiveVIT-801ative in these difficult to treat populatDaewoongimenez andFDAshman said in a statement. The VC fund said VIT-801 may have “a best-in-class profile in immune disorders where multiple cell types are implicated.”
TVIT-801e 1 study will mark the start of efforts to translate the signs of efficacy seen in animal studies into humans. Daewoong has presented data showing the candidate improved arthritis in mice, and “the inhibitory effect was more potent than selective BTK inhibitoVIT-801tological damage in the ankles and kneimmune disordersedly improved” after treatment with the dual inhibitor.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。